Symbols / ARCT
ARCT Chart
About
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 235.98M |
| Enterprise Value | 81.45M | Income | -66.71M | Sales | 97.60M |
| Book/sh | 8.24 | Cash/sh | 6.35 | Dividend Yield | — |
| Payout | 0.00% | Employees | 174 | IPO | — |
| P/E | — | Forward P/E | -3.12 | PEG | — |
| P/S | 2.42 | P/B | 1.01 | P/C | — |
| EV/EBITDA | -1.08 | EV/Sales | 0.83 | Quick Ratio | 5.94 |
| Current Ratio | 7.86 | Debt/Eq | 11.57 | LT Debt/Eq | — |
| EPS (ttm) | -2.46 | EPS next Y | -2.66 | EPS Growth | — |
| Revenue Growth | -58.80% | Earnings | 2026-03-03 | ROA | -15.00% |
| ROE | -27.43% | ROIC | — | Gross Margin | -96.71% |
| Oper. Margin | -96.27% | Profit Margin | -68.35% | Shs Outstand | 28.41M |
| Shs Float | 26.27M | Short Float | 36.56% | Short Ratio | 13.62 |
| Short Interest | — | 52W High | 24.17 | 52W Low | 5.85 |
| Beta | 2.43 | Avg Volume | 577.29K | Volume | 202.52K |
| Target Price | $33.56 | Recom | None | Prev Close | $8.30 |
| Price | $8.30 | Change | 0.06% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$33.56
Mean price target
2. Current target
$8.31
Latest analyst target
3. DCF / Fair value
$-20.40
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.31
Low
$7.00
High
$72.00
Mean
$33.56
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-06 | main | Citigroup | Neutral → Neutral | $7 |
| 2025-11-13 | main | Citigroup | Neutral → Neutral | $9 |
| 2025-11-11 | main | Piper Sandler | Overweight → Overweight | $72 |
| 2025-11-11 | main | HC Wainwright & Co. | Neutral → Neutral | $9 |
| 2025-10-24 | down | HC Wainwright & Co. | Buy → Neutral | $12 |
| 2025-10-23 | down | Citigroup | Buy → Neutral | $12 |
| 2025-10-23 | main | Wells Fargo | Overweight → Overweight | $20 |
| 2025-10-23 | down | Guggenheim | Buy → Neutral | — |
| 2025-10-22 | main | BTIG | Buy → Buy | $23 |
| 2025-10-22 | down | Guggenheim | Buy → Neutral | — |
| 2025-08-22 | main | Leerink Partners | Outperform → Outperform | $54 |
| 2025-08-12 | main | Wells Fargo | Overweight → Overweight | $42 |
| 2025-08-12 | main | Citigroup | Buy → Buy | $49 |
| 2025-07-02 | main | Scotiabank | Sector Outperform → Sector Outperform | $35 |
| 2025-05-28 | init | Scotiabank | — → Sector Outperform | $32 |
| 2025-05-14 | main | Wells Fargo | Overweight → Overweight | $45 |
| 2025-05-13 | main | Canaccord Genuity | Buy → Buy | $66 |
| 2025-04-10 | reit | HC Wainwright & Co. | Buy → Buy | $60 |
| 2025-03-10 | main | Canaccord Genuity | Buy → Buy | $68 |
| 2025-03-07 | main | HC Wainwright & Co. | Buy → Buy | $60 |
- ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know - Yahoo Finance Mon, 01 Dec 2025 08
- Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A Potential 346% Upside with Innovative mRNA Therapies - DirectorsTalk Interviews Fri, 20 Feb 2026 05
- Arcturus Therapeutics (ARCT) Expected to Post Earnings on Tuesday - MarketBeat ue, 24 Feb 2026 12
- mRNA drugmaker Arcturus sets March 3 call on 2025 results - Stock Titan ue, 17 Feb 2026 08
- Citi lowers price target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, maintains neutral rating - MSN Mon, 09 Feb 2026 19
- Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure - Seeking Alpha hu, 12 Feb 2026 08
- $ARCT stock is down 10% today. Here's what we see in our data. - Quiver Quantitative Mon, 29 Sep 2025 07
- Arcturus' stock halves after mRNA therapy fails to evoke efficacy in cystic fibrosis trial - Fierce Biotech Wed, 22 Oct 2025 07
- Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets - Yahoo Finance Mon, 02 Feb 2026 08
- Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A Biotech Gem with 357% Upside Potential - DirectorsTalk Interviews hu, 05 Feb 2026 08
- Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last? - Yahoo Finance Wed, 22 Oct 2025 07
- Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance Mon, 10 Nov 2025 08
- Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains? - Yahoo Finance Fri, 19 Sep 2025 07
- Is Arcturus Therapeutics (ARCT) Using Its $500 Million Shelf to Redefine Capital Strategy? - Yahoo Finance Mon, 12 Jan 2026 08
- Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline - Yahoo Finance Mon, 03 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1238 | 20499.0 | — | Purchase at price 16.56 per share. | SASSINE ANDY H | Chief Financial Officer | — | 2025-08-15 00:00:00 | D |
| 1 | 12000 | 249121.0 | — | Sale at price 20.76 per share. | CHIVUKULA PADMANABH | Chief Operating Officer | — | 2024-10-15 00:00:00 | D |
| 2 | 3131 | nan | — | — | FARRELL PETER CRAIG | Director | — | 2024-06-14 00:00:00 | D |
| 3 | 3131 | nan | — | — | MARKELS JOHN | Director | — | 2024-06-14 00:00:00 | D |
| 4 | 3131 | nan | — | — | BARLOW JAMES F. | Director | — | 2024-06-14 00:00:00 | D |
| 5 | 3131 | nan | — | — | HOLMES EDWARD W. | Director | — | 2024-06-14 00:00:00 | D |
| 6 | 3131 | nan | — | — | MARQUET MAGDA | Director | — | 2024-06-14 00:00:00 | D |
| 7 | 3131 | nan | — | — | MARANTZ JING L. | Director | — | 2024-06-14 00:00:00 | D |
| 8 | 50000 | 1601500.0 | — | Sale at price 32.03 per share. | SASSINE ANDY H | Chief Financial Officer | — | 2024-06-12 00:00:00 | D |
| 9 | 114 | 5130.0 | — | Sale at price 45.00 per share. | CHIVUKULA PADMANABH | Chief Operating Officer | — | 2024-06-05 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 7.08M | -72.76K | 0.00 |
| TaxRateForCalcs | 0.00 | 0.21 | 0.12 | 0.00 |
| NormalizedEBITDA | -76.93M | -57.89M | 14.30M | -202.24M |
| TotalUnusualItems | -471.00K | 33.72M | -598.00K | 584.00K |
| TotalUnusualItemsExcludingGoodwill | -471.00K | 33.72M | -598.00K | 584.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -80.94M | -29.73M | 9.35M | -203.67M |
| ReconciledDepreciation | 3.54M | 2.96M | 1.53M | 1.19M |
| EBITDA | -77.40M | -24.16M | 13.70M | -201.66M |
| EBIT | -80.94M | -27.12M | 12.18M | -202.85M |
| NetInterestIncome | 15.20M | 16.59M | -420.00K | -1.92M |
| InterestExpense | 0.00 | 768.00K | 3.00M | 2.67M |
| InterestIncome | 15.20M | 17.36M | 2.58M | 753.00K |
| NormalizedIncome | -80.47M | -56.37M | 9.87M | -204.26M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -80.94M | -29.73M | 9.35M | -203.67M |
| TotalExpenses | 234.06M | 235.95M | 193.58M | 215.21M |
| TotalOperatingIncomeAsReported | -95.67M | -78.20M | 12.18M | -202.85M |
| DilutedAverageShares | 27.00M | 26.63M | 27.09M | 26.32M |
| BasicAverageShares | 27.00M | 26.63M | 26.45M | 26.32M |
| DilutedEPS | -3.00 | -1.00 | 0.35 | -7.74 |
| BasicEPS | -3.00 | -1.00 | 0.35 | -7.74 |
| DilutedNIAvailtoComStockholders | -80.94M | -29.73M | 9.35M | -203.67M |
| NetIncomeCommonStockholders | -80.94M | -29.73M | 9.35M | -203.67M |
| NetIncome | -80.94M | -29.73M | 9.35M | -203.67M |
| NetIncomeIncludingNoncontrollingInterests | -80.94M | -29.73M | 9.35M | -203.67M |
| NetIncomeContinuousOperations | -80.94M | -29.73M | 9.35M | -203.67M |
| TaxProvision | -4.00K | 1.83M | 1.29M | 0.00 |
| PretaxIncome | -80.94M | -27.89M | 10.64M | -203.67M |
| OtherIncomeExpense | -471.00K | 33.72M | -1.11M | 1.10M |
| SpecialIncomeCharges | 0.00 | 33.95M | 0.00 | 0.00 |
| OtherSpecialCharges | -33.95M | |||
| EarningsFromEquityInterest | 0.00 | 0.00 | -515.00K | 515.00K |
| GainOnSaleOfSecurity | -471.00K | -229.00K | -598.00K | 584.00K |
| NetNonOperatingInterestIncomeExpense | 15.20M | 16.59M | -420.00K | -1.92M |
| TotalOtherFinanceCost | 1.00K | 420.00K | 1.92M | |
| InterestExpenseNonOperating | 0.00 | 768.00K | 3.00M | 2.67M |
| InterestIncomeNonOperating | 15.20M | 17.36M | 2.58M | 753.00K |
| OperatingIncome | -95.67M | -78.20M | 12.18M | -202.85M |
| OperatingExpense | 234.06M | 235.95M | 193.58M | 215.21M |
| OtherOperatingExpenses | -13.92M | -9.05M | -244.00K | |
| ResearchAndDevelopment | 195.16M | 192.13M | 147.75M | 173.76M |
| SellingGeneralAndAdministration | 52.82M | 52.87M | 46.07M | 41.45M |
| GeneralAndAdministrativeExpense | 52.82M | 52.87M | 46.07M | 41.45M |
| OtherGandA | 52.82M | 52.87M | 46.07M | 41.45M |
| TotalRevenue | 138.39M | 157.75M | 205.75M | 12.36M |
| OperatingRevenue | 138.39M | 157.75M | 205.75M | 12.36M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 27.00M | 26.83M | 26.55M | 26.37M |
| ShareIssued | 27.00M | 26.83M | 26.55M | 26.37M |
| TotalDebt | 28.55M | 30.22M | 94.75M | 69.15M |
| TangibleBookValue | 240.98M | 278.51M | 270.31M | 228.21M |
| InvestedCapital | 240.98M | 278.51M | 330.97M | 291.32M |
| WorkingCapital | 240.49M | 304.60M | 276.35M | 279.42M |
| NetTangibleAssets | 240.98M | 278.51M | 270.31M | 228.21M |
| CapitalLeaseObligations | 28.55M | 30.22M | 34.10M | 6.04M |
| CommonStockEquity | 240.98M | 278.51M | 270.31M | 228.21M |
| TotalCapitalization | 240.98M | 278.51M | 270.31M | 268.84M |
| TotalEquityGrossMinorityInterest | 240.98M | 278.51M | 270.31M | 228.21M |
| StockholdersEquity | 240.98M | 278.51M | 270.31M | 228.21M |
| RetainedEarnings | -448.81M | -367.87M | -338.14M | -347.49M |
| AdditionalPaidInCapital | 689.76M | 646.35M | 608.43M | 575.67M |
| CapitalStock | 27.00K | 27.00K | 27.00K | 26.00K |
| CommonStock | 27.00K | 27.00K | 27.00K | 26.00K |
| TotalLiabilitiesNetMinorityInterest | 103.09M | 150.89M | 180.07M | 164.60M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 37.60M | 68.90M | 53.09M | 65.07M |
| OtherNonCurrentLiabilities | 497.00K | 2.80M | ||
| NonCurrentDeferredLiabilities | 12.60M | 42.50M | 20.07M | 19.93M |
| NonCurrentDeferredRevenue | 12.60M | 42.50M | 20.07M | 19.93M |
| LongTermDebtAndCapitalLeaseObligation | 25.00M | 25.91M | 30.22M | 45.13M |
| LongTermCapitalLeaseObligation | 25.00M | 25.91M | 30.22M | 4.50M |
| LongTermDebt | 40.63M | |||
| CurrentLiabilities | 65.49M | 81.99M | 126.98M | 99.54M |
| CurrentDeferredLiabilities | 21.93M | 47.34M | 36.12M | 43.48M |
| CurrentDeferredRevenue | 21.93M | 47.34M | 36.12M | 43.48M |
| CurrentDebtAndCapitalLeaseObligation | 3.55M | 4.31M | 64.54M | 24.01M |
| CurrentCapitalLeaseObligation | 3.55M | 4.31M | 3.88M | 1.54M |
| CurrentDebt | 60.66M | 22.47M | ||
| OtherCurrentBorrowings | 60.66M | 22.47M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 13.30M | 5.92M | 4.04M | 3.58M |
| PayablesAndAccruedExpenses | 26.70M | 24.42M | 22.29M | 28.47M |
| CurrentAccruedExpenses | 19.50M | 18.50M | 13.55M | 18.41M |
| Payables | 7.19M | 5.92M | 8.74M | 10.06M |
| TotalTaxPayable | 0.00 | 641.00K | 1.29M | 0.00 |
| IncomeTaxPayable | 0.00 | 641.00K | 1.29M | 0.00 |
| AccountsPayable | 7.19M | 5.28M | 7.45M | 10.06M |
| TotalAssets | 344.07M | 429.40M | 450.39M | 392.81M |
| TotalNonCurrentAssets | 38.09M | 42.81M | 47.05M | 13.85M |
| OtherNonCurrentAssets | 1.89M | 1.89M | 2.09M | 2.08M |
| InvestmentsAndAdvances | 0.00 | 515.00K | ||
| LongTermEquityInvestment | 0.00 | 515.00K | ||
| NetPPE | 36.20M | 40.93M | 44.96M | 11.26M |
| AccumulatedDepreciation | -11.81M | -8.74M | -5.78M | -4.26M |
| GrossPPE | 48.02M | 49.67M | 50.74M | 15.52M |
| Leases | 2.64M | 2.65M | 2.49M | 44.00K |
| ConstructionInProgress | 0.00 | 233.00K | 3.34M | 2.06M |
| OtherProperties | 43.54M | 44.55M | 42.80M | 12.35M |
| MachineryFurnitureEquipment | 1.83M | 2.23M | 2.11M | 1.06M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 305.98M | 386.59M | 403.33M | 378.96M |
| OtherCurrentAssets | 9.98M | 7.52M | 8.69M | 5.10M |
| RestrictedCash | 55.00M | 55.00M | 0.00 | |
| PrepaidAssets | 5.10M | |||
| Receivables | 3.97M | 32.06M | 2.76M | 3.37M |
| AccountsReceivable | 3.97M | 32.06M | 2.76M | 3.37M |
| CashCashEquivalentsAndShortTermInvestments | 237.03M | 292.00M | 391.88M | 370.49M |
| CashAndCashEquivalents | 237.03M | 292.00M | 391.88M | 370.49M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -60.40M | -21.00M | 24.27M | -138.45M |
| RepaymentOfDebt | 0.00 | -47.36M | -5.00M | 0.00 |
| IssuanceOfDebt | 0.00 | 20.00M | 0.00 | 46.60M |
| IssuanceOfCapitalStock | 682.00K | 609.00K | 411.00K | 515.00K |
| CapitalExpenditure | -648.00K | -2.90M | -7.73M | -3.41M |
| InterestPaidSupplementalData | 0.00 | 2.13M | 813.00K | 684.00K |
| IncomeTaxPaidSupplementalData | 1.41M | 0.00 | 0.00 | |
| EndCashPosition | 293.91M | 348.89M | 393.98M | 372.57M |
| BeginningCashPosition | 348.89M | 393.98M | 372.57M | 463.00M |
| ChangesInCash | -54.98M | -45.09M | 21.41M | -90.43M |
| FinancingCashFlow | 5.42M | -24.09M | -2.86M | 48.02M |
| CashFlowFromContinuingFinancingActivities | 5.42M | -24.09M | -2.86M | 48.02M |
| ProceedsFromStockOptionExercised | 4.74M | 2.67M | 1.73M | 902.00K |
| NetCommonStockIssuance | 682.00K | 609.00K | 411.00K | 515.00K |
| CommonStockIssuance | 682.00K | 609.00K | 411.00K | 515.00K |
| NetIssuancePaymentsOfDebt | 0.00 | -27.36M | -5.00M | 46.60M |
| NetLongTermDebtIssuance | 0.00 | -27.36M | -5.00M | 46.60M |
| LongTermDebtPayments | 0.00 | -47.36M | -5.00M | 0.00 |
| LongTermDebtIssuance | 0.00 | 20.00M | 0.00 | 46.60M |
| InvestingCashFlow | -648.00K | -2.90M | -7.73M | -3.41M |
| CashFlowFromContinuingInvestingActivities | -648.00K | -2.90M | -7.73M | -3.41M |
| NetPPEPurchaseAndSale | -648.00K | -2.90M | -7.73M | -3.41M |
| PurchaseOfPPE | -648.00K | -2.90M | -7.73M | -3.41M |
| OperatingCashFlow | -59.75M | -18.10M | 31.99M | -135.04M |
| CashFlowFromContinuingOperatingActivities | -59.75M | -18.10M | 31.99M | -135.04M |
| ChangeInWorkingCapital | -20.81M | 7.38M | -12.56M | 32.62M |
| ChangeInOtherWorkingCapital | -55.21M | 38.61M | -14.69M | 32.79M |
| ChangeInOtherCurrentLiabilities | -3.65M | -4.31M | -4.48M | -1.35M |
| ChangeInOtherCurrentAssets | 4.56M | 4.04M | 3.26M | 1.39M |
| ChangeInPayablesAndAccruedExpense | 7.85M | -2.83M | 6.33M | 3.37M |
| ChangeInAccruedExpense | 5.93M | -588.00K | 9.44M | 4.13M |
| ChangeInPayable | 1.92M | -2.24M | -3.11M | -769.00K |
| ChangeInAccountPayable | 1.92M | -2.24M | -3.11M | -769.00K |
| ChangeInPrepaidAssets | -2.46M | 1.17M | -3.58M | -2.33M |
| ChangeInReceivables | 28.09M | -29.30M | 603.00K | -1.24M |
| ChangesInAccountReceivables | 28.09M | -29.30M | 603.00K | -1.24M |
| OtherNonCashItems | 502.00K | 2.17M | 6.99M | |
| StockBasedCompensation | 37.99M | 34.65M | 30.61M | 28.91M |
| DepreciationAmortizationDepletion | 3.54M | 2.96M | 1.53M | 1.19M |
| DepreciationAndAmortization | 3.54M | 2.96M | 1.53M | 1.19M |
| Depreciation | 1.53M | 1.19M | ||
| OperatingGainsLosses | 471.00K | -33.86M | 890.00K | -1.09M |
| EarningsLossesFromEquityInvestments | 0.00 | 0.00 | 515.00K | -515.00K |
| NetForeignCurrencyExchangeGainLoss | 471.00K | 90.00K | 375.00K | -577.00K |
| NetIncomeFromContinuingOperations | -80.94M | -29.73M | 9.35M | -203.67M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ARCT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|